Rui Li, 58Newton, MA

7064180, Jun 20, 2006

Jan 11, 2001

09/758493

M. Amin Arnaout - Chestnut Hill MA, US
Rui Li - Medford MA, US
Jian-Ping Xiong - Quincy MA, US

The General Hospital Corporation - Boston MA

A61K 38/04

530324

Polypeptides comprising all or part of a variant integrin α subunit A domain or a variant integrin β subunit A-like domain are described. In solution or in membrane-associated form, the A domain or the A-like domain of the polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine residue (described in greater detail below) is absent. The isoleucine can be either deleted or replaced with different amino acids residue, preferably a smaller or less hydrophobic amino acid residue, e. g. , alanine or glycine. Because the variant integrin polypeptides of the invention exist in solution or in membrane-associated form predominantly in a high affinity conformation, they are useful in screening assays for the identification of molecules that bind to (and/or mediate the activity of) an integrin. They are also useful for generating antibodies, e. g. , monoclonal antibodies, which bind to the high affinity form of an integrin.

7153944, Dec 26, 2006

Mar 13, 2001

09/805354

M. Amin Arnaout - Chestnut Hill MA, US
Rui Li - Medford MA, US
Jian-Ping Xiong - Quincy MA, US

The General Hospital Corporation - Boston MA

C07K 1/107
G01N 33/53

530402, 435 71

Polypeptides comprising all or part of a variant integrin α subunit A domain or a variant integrin β subunit A-like domain are described. In solution or in membrane-associated form, the A domain or the A-like domain of the polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine residue (described in greater detail below) is absent. The isoleucine can be either deleted or replaced with different amino acids residue, preferably a smaller or less hydrophobic amino acid residue, e. g. , alanine or glycine. Because the variant integrin polypeptides of the invention exist in solution or in membrane-associated form predominantly in a high affinity conformation, they are useful in screening assays for the identification of molecules that bind to (and/or mediate the activity of) an integrin. They are also useful for generating antibodies, e. g. , monoclonal antibodies, which bind to the high affinity form of an integrin.

7323552, Jan 29, 2008

May 10, 2002

10/144259

M. Amin Arnaout - Chestnut Hill MA, US
Rui Li - Medford MA, US
Jian-Ping Xiong - Quincy MA, US

The General Hospital Corporation - Boston MA

C07K 1/107
A61K 38/04
G01N 33/53

530402, 435 71, 530324

Polypeptides comprising all or part of a variant integrin α subunit A domain and its flanking region are described. In solution or in membrane-associated form, the A domain polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine or glutamic acid residue is altered. For example, the glutamic acid can be either deleted or replaced with different amino acids residue, e. g. , glutamine, aspartic acid, or alanine The variant integrin polypeptides of the invention selectively impair binding of activation-dependent ligands, but not independent ligands. They are useful in screening assays for the identification of molecules that enhance binding of variant polypeptides with impaired binding. In addition, they are useful in distinguishing between activation-dependent ligands and activation-independent ligands. They are also useful for generating antibodies, e. g.

8218869, Jul 10, 2012

Mar 29, 2009

12/413593

Fatih M. Porikli - Watertown MA, US
Rui Li - Brookline MA, US

Mitsubishi Electric Research Laboratories, Inc. - Cambridge MA

G06K 9/34

382173

The embodiments of the invention describe a method for segmenting an image. We perform an initial segmentation of the image to produce a previous segmented region and segment iteratively the image using a spatial random walk based on a shape prior of the previous segmented region to produce a next segmented region. We compare the next segmented region with the previous segmented region, and repeat the segmenting and the comparing until the previous and next segmented regions converge. After that, we select the next segmented region as a final segmented region.

2009002, Jan 22, 2009

Jan 28, 2008

12/021074

M. Amin Arnaout - Chestnut Hill MA, US
Rui Li - Medford MA, US
Jian-Ping Xiong - Quincy MA, US

G01N 33/566
C07K 16/18

436501, 5303879

Polypeptides comprising all or part of a variant integrin α subunit A domain and its flanking region are described. In solution or in membrane-associated form, the A domain polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine or glutamic acid residue is altered. For example, the glutamic acid can be either deleted or replaced with different amino acids residue, e.g., glutamine, aspartic acid, or alanine The variant integrin polypeptides of the invention selectively impair binding of activation-dependent ligands, but not independent ligands. They are useful in screening assays for the identification of molecules that enhance binding of variant polypeptides with impaired binding. In addition, they are useful in distinguishing between activation-dependent ligands and activation-independent ligands. They are also useful for generating antibodies, e.g., monoclonal antibodies, which bind to the impaired form of an integrin. Some such antibodies recognize an epitope that is either not present or not accessible on an integrin that is in the high affinity conformation. The variant integrin polypeptides of the invention can be derived from any integrin α subunit that could be used therapeutically.